– Mean body weight loss of 11.1% in participants who received injections of 2.4 mg XW003 once weekly for 18 weeks
– 88.5% and 57.7% of participants who received 2.4 mg of XW003 for 18 weeks achieved weight loss of ≥5% and ≥10% or
– XW003 was safe and well-tolerated, with an adverse event profile consistent with other GLP-1 analogues
SAN FRANCISCO and HANGZHOU, China, October 27, 2022 /PRNewswire/ — Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies to treat metabolic diseases, today announced positive results from an interim analysis at its current stage 2 B clinical study of XW003 (ecnoglutide) in obese patients. XW003 is a novel long-acting glucagon-like peptide-1 (GLP-1) analog being developed for the treatment of type 2 diabetes and obesity.
XW003 is currently being evaluated in a multi-center, open-label, active-controlled phase 2 B clinical study with participants with a body mass index (BMI) ≥ 30 kg/m2. The study will be conducted at nine sites in Australia and New Zealand, with 206 enrolled participants. Participants were randomized to receive target doses of XW003 at 1.2, 1.8, or 2.4 mg as once-weekly injections or liraglutide (Saxenda®) at 3.0 mg as once-daily injections for 26 weeks. Doses were increased by titration for up to 14 weeks before the target dose was reached. The interim analysis was conducted after approximately 140 participants had completed 18 weeks of treatment. At the start of the study, the participants had a mean body weight of 99.6 kg and a BMI of 34.9 kg/m2.
After 18 weeks of treatment, participants who received XW003 2.4 mg weekly achieved a mean body weight reduction of 11.1% (10.9 kg) from baseline compared to 7.9% (8.1 kg) in participants who received who received 3.0 mg liraglutide injections daily (P=0.009). After 18 weeks of treatment, the proportion of participants achieving ≥5% body weight loss from baseline was 88.5% for XW003 2.4 mg and 70.4% for liraglutide, while these…
